Plain-English translation of NCT07406139 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Hemophilia research guide →Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing prothrombin complex concentrate () to help people with hemophilia A who have developed inhibitors — a complication where the body's immune system attacks the standard clotting factor treatment, making it stop working. The medication works by helping your blood clot through a different pathway that doesn't rely on the blocked clotting factor. Researchers want to see if this treatment can safely and effectively stop bleeding episodes in this group of patients.
People with hemophilia A who develop inhibitors face a serious problem: their standard treatment no longer works, leaving them at risk for dangerous bleeding and joint damage. While other bypass treatments exist, they are either unavailable or very expensive in China, so this trial is testing whether this medication could be a more practical option for these patients.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive prothrombin complex concentrate treatment when you have bleeding episodes, and the study team would monitor how well it works at stopping the bleeding and whether you experience any side effects. The study involves multiple visits to a hospital or clinic in China over the course of the trial period, during which your blood work and overall response to treatment will be checked. In total, the researchers plan to enroll about 30 participants across multiple centers to gather information about this medication's safety and effectiveness.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China